Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Creo Medical ( (GB:CREO) ) has shared an announcement.
Creo Medical’s Speedboat® technology, a minimally invasive device for treating complex colorectal polyps, has been adopted for a pilot program by the Aneurin Bevan University Health Board, marking the first such initiative in Wales. This pilot is expected to improve patient outcomes, reduce surgical waiting times, and potentially serve as a model for wider adoption across other health boards, highlighting the innovative approach of Welsh healthcare systems and Creo’s strategic positioning in the medical device industry.
More about Creo Medical
Creo Medical Group plc is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. The company’s focus is on delivering advanced energy solutions for endoscopy, with technologies like CROMA powered by Kamaptive, which provide flexible and precise surgical capabilities. Their products aim to offer safer, less invasive, and cost-efficient options for surgical procedures.
YTD Price Performance: -8.21%
Average Trading Volume: 831,794
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £73.83M
See more data about CREO stock on TipRanks’ Stock Analysis page.
